Source: Rheumatology international. Unidade: FM
Subjects: COVID-19, DIABETES MELLITUS, VACINAÇÃO, ESTUDOS TRANSVERSAIS
ABNT
PANCHAWAGH, Suhrud et al. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatology international, v. 44, n. 1, p. 73-80, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58770. Acesso em: 13 nov. 2024.APA
Panchawagh, S., Ravichandran, N., Barman, B., Nune, A., Javaid, M., Gracia-Ramos, A. E., et al. (2024). COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatology international, 44( 1), 73-80. doi:10.1007/s00296-023-05496-yNLM
Panchawagh S, Ravichandran N, Barman B, Nune A, Javaid M, Gracia-Ramos AE, Day J, Joshi M, Kuwana M, Shinjo SK. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group [Internet]. Rheumatology international. 2024 ; 44( 1): 73-80.[citado 2024 nov. 13 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58770Vancouver
Panchawagh S, Ravichandran N, Barman B, Nune A, Javaid M, Gracia-Ramos AE, Day J, Joshi M, Kuwana M, Shinjo SK. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group [Internet]. Rheumatology international. 2024 ; 44( 1): 73-80.[citado 2024 nov. 13 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58770